secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001213900-25-089845
Event type: other
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix subsidiary Proteomedix licenses manufacturing IP for PancreaSure test to Immunovia
--------------------------------------------------------------------------------

- Proteomedix provides master cell lines and IP for three of five PancreaSure biomarkers.
- Immunovia pays $700K total: two $300K payments (Sep 2025, Mar 2026) plus $100K for materials.
- Immunovia to pay 3% royalty on net sales of PancreaSure from 2026 through 2032.
- Deal enables Immunovia to purchase reagents directly from Proteomedix's supplier.
- Onconetix remains focused on commercializing its own Proclarix prostate cancer test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025089845/0001213900-25-089845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025089845/ea0258196-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-089845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer